Ventus doses first participant in Phase I clinical trial of VENT|03

Ventus doses first participant in Phase I clinical trial of VENT-03

Ventus has dosed the first subject in a Phase I clinical trial of its cGAS inhibitor, VENT-03, for the treatment of cardiometabolic ...

Ventus Therapeutics Announces First Participant Dosed in Clinical ...

In addition, Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor, to Novo Nordisk A/S. These programs exemplify Ventus' ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

This first-in-human Phase 1 trial is designed to fully explore the pharmacokinetics, pharmacodynamics, and safety of VENT-03 across a broad range of single and ...

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor.

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

This first-in-human Phase 1 trial is designed to fully explore the pharmacokinetics, pharmacodynamics, and safety of VENT-03 across a broad ...

Ventus Therapeutics Begins Dosing in NLRP3 Inhibitor Study ...

The first participant in a Phase 1 clinical study for NNC6022-0001 has been successfully dosed. This compound, an oral NLRP3 inhibitor, was initially known as ...

Dosing begins in Phase 1 trial of VENT-03, potential cGAS inhibitor

A first person has been dosed in a Phase 1 clinical trial of VENT-03, Ventus Therapeutics' oral treatment candidate for lupus and other inflammatory diseases.

Ventus Therapeutics' partner Novo Nordisk doses first participant in ...

Ventus Therapeutics' partner Novo Nordisk doses first participant in phase 1 clinical study for NNC6022-0001, an oral NLRP3 inhibitor.

Ventus Therapeutics Announces First Participant Dosed in Clinical ...

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk · Article ...

Ventus Therapeutics starts trials on VENT-03, a drug to inhibit cGAS ...

The drug is currently in Phase 1 of clinical development, indicating its early stage of testing in humans. Further research and clinical trials ...

Hung Trinh on LinkedIn: Ventus Therapeutics Announces ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS ...

Marcelo Bigal, MD, PhD: VENT-03's Modality Offers Hope for ...

Ventus Therapeutics recently initiated a phase 1 clinical trial for ... The trial, involving the dosing of the first participant, aims ...

Ventus Therapeutics Announces First Participant Dosed in Clinical ...

The Phase 1 study is designed to fully explore the pharmacokinetics, pharmacodynamics, and safety of NNC6022-0001 across a broad range of doses ...

Ventus Therapeutics' partner Novo Nordisk doses first participant in ...

Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that its partner, Novo Nordisk, has successfully dosed the ...

Ventus Therapeutics' Post - LinkedIn

Today, we shared results from the Phase 1 clinical trial of VENT-03, the first cGAS inhibitor to successfully complete a first-in-human ...

Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor

Novo Nordisk has dosed the first subject in a Phase I clinical trial of the oral NLRP3 inhibitor NNC6022-0001 (formerly known as VENT-01) as a potential ...

Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of ...

Ventus' first target screen was conducted in 2020, which led to the nomination of three development candidates in 2022, including: VENT-03, a ...

Dosing begins in Phase 1 trial of VENT-02 therapy for Parkinson's

Ventus Therapeutics has dosed the first participant in its Phase 1 trial testing VENT-02, a novel oral therapy that features an inhibitor that reaches the ...

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.

NNC-6022-0001 - Drug Targets, Indications, Patents - Synapse

“Our next trial for VENT-02, a Phase 1b trial in patients with Parkinson's disease, will evaluate multiple doses and dose regimens against a placebo control and ...